Efficacy and Safety of Bevacizumab Plus Oxaliplatin- or Irinotecan-Based Doublet Backbone Chemotherapy as the First-Line Treatment of Metastatic Colorectal Cancer: A Systematic Review and Meta-analysis
ConclusionsThe BEV-IR regimen was superior in improving progression-free survival as the first-line treatment for metastatic colorectal cancer. The two different doublet regimens combined with BEV had their specific features of adverse events.
Source: Drug Safety - Category: Drugs & Pharmacology Source Type: research
More News: Avastin | Bleeding | Brain | Cancer | Cancer & Oncology | Chemotherapy | Colorectal Cancer | Conferences | Databases & Libraries | Drugs & Pharmacology | Eloxatin | Neurology | Study | Thrombocytopenia | Thrombosis